IMRXImmuneering CorporationHealthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $4.45 · now $4.45 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, IMRX has typically landed between $2.85 and $7.37 — a range of −35.9% to +65.7% from the issuance price $4.45.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

1,267 overlapping 1 month windows · 2021-07-30 – 2026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.7–56.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($4.45) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where IMRX has typically landed a month from the 2026-09-16 close of $4.45 — the range is history, not a prediction.

$2.85worst · -35.9%$7.37best · +65.7%
  • now $4.45 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $4.2 (-5.6%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $3.48–$4.93
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $2.85–$7.37
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 1,267 windows spanning 2021-07-30 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2024-02-14−70.5%−70.5%+4.3%
2024-03-07−68.3%−71.4%+0.0%
2024-03-08−66.6%−70.9%+0.0%
3 best
2024-08-21+186.6%−6.3%+186.6%
2024-08-22+173.3%+0.0%+205.7%
2024-08-23+172.9%+0.0%+200.0%

1,267 overlapping windows · 2021-07-30 – 2026-09-16 · not cherry-picked

Pending catalysts

  • June 2028 — Trial primary completion: Phase 3 primary completion: Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma (source, as of 2026-08-14)

Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~6 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
0%
−22.7%
n=5
Feb
60%
−2.0%
n=5
Mar
40%
+5.9%
n=5
Apr
20%
−16.6%
n=5
May
40%
+2.5%
n=5
Jun
60%
+25.4%
n=5
Jul
60%
−1.2%
n=5
Aug
50%
+16.6%
n=6
Sep
67%
+47.6%
n=6
Oct
20%
−7.4%
n=5
Nov
40%
−10.5%
n=5
Dec
40%
−10.1%
n=5

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$9$32026-06-23: 1 insider purchase, $11K — Zeskind Benjamin J.2026-06-15: 1 insider purchase, $25K — Hall Brett Matthew2026-01-16: 1 insider purchase, $25K — Brakewood Harold Eugene2026-01-15: 2 insider purchases, $112K — Schall Thomas J., Hall Brett Matthew2026-01-13: 1 insider purchase, $11K — Neufeld Leah R2026-01-12: 1 insider purchase, $87K — Feinberg Peter2025-10-03: 1 insider purchase, $50K — Feinberg Peter2025-10-01: 3 insider purchases, $14K — Bookman Michael, Neufeld Leah R, Morales Mallory2025-09-30: 1 insider purchase, $53K — Feinberg Peter2025-09-29: 1 insider purchase, $36K — Feinberg Peter2025-09: 2 open-market purchases, $89K2025-10: 4 open-market purchases, $64K2026-01: 5 open-market purchases, $234K2026-06: 2 open-market purchases, $36K↑ buys↓ salesdirector Zeskind Benjamin J. — Purchase on 2026-06-23, filed 1 day after the tradeofficer Hall Brett Matthew — Purchase on 2026-06-15, filed 1 day after the tradeofficer Brakewood Harold Eugene — Purchase on 2026-01-16, filed 5 days after the tradedirector Schall Thomas J. — Purchase on 2026-01-15, filed 5 days after the tradeofficer Hall Brett Matthew — Purchase on 2026-01-15, filed 1 day after the tradeofficer Neufeld Leah R — Purchase on 2026-01-13, filed 2 days after the tradedirector Feinberg Peter — Purchase on 2026-01-12, filed 2 days after the tradedirector Feinberg Peter — Purchase on 2025-10-03, filed 4 days after the tradeofficer Bookman Michael — Purchase on 2025-10-01, filed 1 day after the tradeofficer Neufeld Leah R — Purchase on 2025-10-01, filed 1 day after the tradeofficer Morales Mallory — Purchase on 2025-10-01, filed 1 day after the tradedirector Feinberg Peter — Purchase on 2025-09-30, filed 1 day after the tradedirector Feinberg Peter — Purchase on 2025-09-29, filed 1 day after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-06-23Zeskind Benjamin J.directorPurchase2,400 @ $4.56$11K+0.1% of holding−3.9%not yet — horizon still open2,315,252Form 4 · filed 1 day after the trade
2026-06-15Hall Brett MatthewofficerPurchase6,035 @ $4.15$25K+1.6% of holding+14.4%not yet — horizon still open382,531Form 4 · filed 1 day after the trade
2026-01-16Brakewood Harold EugeneofficerPurchase5,250 @ $4.76$25K+90.5% of holding+10.6%−11.4%11,050Form 4 · filed 5 days after the trade
2026-01-15Schall Thomas J.directorPurchase21,645 @ $4.67$101K+40.9% of holding+11.7%−15.3%74,530Form 4 · filed 5 days after the trade
2026-01-15Hall Brett MatthewofficerPurchase2,298 @ $4.57$11K+0.6% of holding+11.7%−15.3%376,496Form 4 · filed 1 day after the trade
2026-01-13Neufeld Leah RofficerPurchase2,626 @ $4.15$11K+11.2% of holding+21.6%+6.7%25,970Form 4 · filed 2 days after the trade
2026-01-12Feinberg PeterdirectorPurchase20,000 @ $4.35$87K+17.3% of holding+20.1%+13.1%135,441Form 4 · filed 2 days after the trade
2025-10-03Feinberg PeterdirectorPurchase7,500 @ $6.67$50K+5.0% of holding+6.3%−12.6%156,766Form 4 · filed 4 days after the trade
2025-10-01Bookman MichaelofficerPurchase1,020 @ $6.83$7K+26.5% of holding−0.9%−13.0%4,870Form 4 · filed 1 day after the trade
2025-10-01Neufeld Leah RofficerPurchase800 @ $6.38$5K+3.5% of holding−0.9%−13.0%23,344Form 4 · filed 1 day after the trade
2025-10-01Morales MalloryofficerPurchase300 @ $6.39$2K+1.1% of holding−0.9%−13.0%27,533Form 4 · filed 1 day after the trade
2025-09-30Feinberg PeterdirectorPurchase7,500 @ $7.03$53K+5.3% of holding−13.9%−22.8%149,266Form 4 · filed 1 day after the trade
2025-09-29Feinberg PeterdirectorPurchase5,000 @ $7.18$36K+3.7% of holding−7.4%−20.5%141,766Form 4 · filed 1 day after the trade
2025-07-02Zeskind Benjamin J.directorPurchase7,015 @ $3.53$25K+0.3% of holding−6.3%+72.7%2,312,852Form 4 · filed 1 day after the trade
2025-07-02HAUSMAN DIANAdirectorPurchase3,000 @ $3.62$11Kownership Δ n/a−6.3%+72.7%3,000Form 4 · filed 5 days after the trade
2025-07-02HAUSMAN DIANAdirectorPurchase2,500 @ $3.60$9Kownership Δ n/a−6.3%+72.7%2,500Form 4 · filed 5 days after the trade
2025-07-02Neufeld Leah RofficerPurchase700 @ $3.57$2K+7.0% of holding−6.3%+72.7%10,729Form 4 · filed 5 days after the trade
2025-07-01Zeskind Benjamin J.directorPurchase2,985 @ $3.38$10K+0.1% of holding−2.3%+83.8%2,305,837Form 4 · filed 2 days after the trade
2025-06-27Schall Thomas J.directorPurchase9,500 @ $3.66$35K+21.9% of holding+0.9%+77.7%52,885Form 4 · filed 3 days after the trade
2025-06-23Hall Brett MatthewofficerPurchase6,007 @ $2.43$15K+1.7% of holding+62.4%+117.5%359,318Form 4 · filed 1 day after the trade
2025-06-20Hall Brett MatthewofficerPurchase7,415 @ $2.70$20K+2.1% of holding+59.0%+107.3%353,311Form 4 · filed 4 days after the trade
2025-06-20Brakewood Harold EugeneofficerPurchase1,900 @ $2.53$5K+48.7% of holding+59.0%+107.3%5,800Form 4 · filed 4 days after the trade
2025-06-18Feinberg PeterdirectorPurchase25,000 @ $2.53$63K+22.4% of holding+47.5%+85.5%136,766Form 4 · filed 5 days after the trade
2025-06-18Zeskind Benjamin J.directorPurchase21,000 @ $2.39$50K+0.9% of holding+47.5%+85.5%2,302,852Form 4 · filed 2 days after the trade
2025-06-17Schall Thomas J.directorPurchase40,485 @ $2.21$89K+1396.0% of holding+121.6%+201.1%43,385Form 4 · filed 1 day after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

36 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-07-16Gengos AndrewdirectorAward / grant650,000650,000Form 4
2026-06-11CARPENTER ROBERT JdirectorAward / grant33,35033,350Form 4
2026-06-11Feinberg PeterdirectorAward / grant33,35033,350Form 4
2026-06-11HAUSMAN DIANAdirectorAward / grant33,35033,350Form 4
2026-06-11KEATING LAURIEdirectorAward / grant33,35033,350Form 4
2026-06-11Schall Thomas J.directorAward / grant33,35033,350Form 4
2026-03-13Neufeld Leah RofficerAward / grant3,62829,598Form 4
2026-02-03Brakewood Harold EugeneofficerAward / grant140,000140,000Form 4
2026-02-03Matushansky IgorofficerAward / grant140,000140,000Form 4
2026-02-03Morales MalloryofficerAward / grant140,000140,000Form 4
2026-02-03Neufeld Leah RofficerAward / grant140,000140,000Form 4
2026-02-03Bookman MichaelofficerAward / grant176,000176,000Form 4
2026-02-03Zeskind Benjamin J.directorAward / grant688,000688,000Form 4
2026-02-03Hall Brett MatthewofficerAward / grant344,000344,000Form 4
2026-01-01KEATING LAURIEdirectorAward / grant7,8887,888Form 4
2026-01-01Feinberg PeterdirectorAward / grant7,8887,888Form 4
2025-09-15Hall Brett MatthewofficerAward / grant14,880374,198Form 4
2025-09-15Morales MalloryofficerAward / grant14,49727,233Form 4
2025-09-15Neufeld Leah RofficerAward / grant11,81522,544Form 4
2025-06-13CARPENTER ROBERT JdirectorAward / grant33,35033,350Form 4
2025-06-13Feinberg PeterdirectorAward / grant33,35033,350Form 4
2025-06-13Schall Thomas J.directorAward / grant33,35033,350Form 4
2025-06-13HAUSMAN DIANAdirectorAward / grant33,35033,350Form 4
2025-06-13BERMAN ANN EdirectorAward / grant33,35033,350Form 4
2025-06-13KEATING LAURIEdirectorAward / grant33,35033,350Form 4
2025-03-21Matushansky IgorofficerAward / grant118,000118,000Form 4
2025-02-05Neufeld Leah RofficerAward / grant110,000110,000Form 4
2025-02-05Morales MalloryofficerAward / grant110,000110,000Form 4
2025-02-05Bookman MichaelofficerAward / grant110,000110,000Form 4
2025-02-05Brakewood Harold EugeneofficerAward / grant100,000100,000Form 4
2025-02-05Zeskind Benjamin J.directorAward / grant480,000480,000Form 4
2025-02-05Hall Brett MatthewofficerAward / grant240,000240,000Form 4
2025-01-01BERMAN ANN EdirectorAward / grant23,48523,485Form 4
2025-01-01BERMAN ANN EdirectorAward / grant17,61417,614Form 4
2025-01-01Feinberg PeterdirectorAward / grant23,48523,485Form 4
2025-01-01KEATING LAURIEdirectorAward / grant23,48523,485Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.